IncellDx, Inc. Signs Exclusive License with Claremont BioSolutions to Commercialize Novel Liquid-Based Biopsy Technology

 Companies’ Combined Technology Produces a “Universal” Sample from Liquid, Fresh or Formalin-Fixed Paraffin Embedded (FFPE) Tissue for Multiplexed Cell Analysis by Flow or Image Cytometry

MENLO PARK, Calif. - Tuesday, April 14th 2015 [ME NewsWire]

(BUSINESS WIRE)--IncellDx, Inc. announced today the signing of a worldwide, exclusive license and supply agreement with Claremont BioSolutions (Upland, CA) to couple their enzyme-free tissue homogenization technology with IncellDx’s patented reagents. The combination forms a sample preparation system called IncellPrep™ Liquid Biopsy, to prepare “universal” cell suspensions formed from either fresh or FFPE tissue. The IncellPrep Liquid Biopsy can be used with IncellDx reagents for multiplex detection of protein, mRNA, and DNA in intact cells by flow or image cytometry.

Bruce Patterson, M.D., CEO of IncellDx commented, “This exciting marriage of technologies circumvents the problems of using different technologies for different specimen types by creating a 'Universal Specimen.' This will allow IncellDx to compete in the histology and immunohistochemistry (IHC) space with our single cell multiplex technology in cancer and infectious disease.”

“The IncellDx liquid biopsy technology is likely to have a major impact in cancer diagnostics and ClaremontBio is pleased that our unique cell dispersion disposables will help to make that possible,” commented Gary Blackburn, Ph.D., CEO of Claremont BioSolutions.

About IncellDx, Inc.

IncellDx, Inc. (www.incelldx.com) is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, lung cancer, HIV/AIDS, hepatitis, and organ transplant rejection. For more information, please visit our website.

About Claremont BioSolutions, LLC.

Claremont BioSolutions (www.ClaremontBio.com) is a privately held, emerging growth technology company specializing in miniaturized, disposable devices and instruments that provide solutions to what is recognized as the “bottleneck” of DNA diagnostics – sample preparation. The company has developed proprietary disposable devices that employ micro-motors to perform very efficient mechanical tissue homogenization, cell lysis, and nucleic acid extraction.    

Contacts

for IncellDx

Eric Hass, 650-777-7630    









Permalink: http://me-newswire.net/news/14287/en